Zymeworks’ (ZYME) Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 20, 2022 9:15 AM EDTOpportunistic proposal from activist shareholder substantially undervalues Zymeworks and is not in the best interests of shareholders Shareholders are right to question the motive behind an activist proposal that was concurrently released to the media and sent to the company without any previous engagement on the subject Management reiterates focus on execution of plan to lead the next wave of novel antibody drug conjugates and multispecific antibody therapeutics for oncology Company remains focused on the... More
